Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus sitagliptin monotherapy assessed by CGM in newly diagnosed type 2 diabetes
ChiCTR1900026285Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoints: Continuous glucose monitoring, Intra-day blood glucose fluctuation and 1 more. Started Jul 2017; status: recruiting.
02
Drugs
dapagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900026285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026285.